Abstract
• Cardiac transplantation for amyloidosis was once considered contraindicated owing to unacceptably high morbidity/mortality rates. • Increased therapeutic options for AL and ATTR amyloidosis and improved pre-transplantation screening practices have led to markedly improved transplant outcomes over the past 10-15 years. • Mechanical circulatory support options remain limited but can be considered in selected patients, particularly for those with larger ventricular cavities. • Transplant prioritization rules may need to be reconsidered for amyloidosis patients to adequately prioritize AL amyloidosis patients, who are at increased risk of pre-transplantation mortality.